BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19042053)

  • 1. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
    Carteni G; Manegold C; Garcia GM; Siena S; Zielinski CC; Amadori D; Liu Y; Blatter J; Visseren-Grul C; Stahel R
    Lung Cancer; 2009 May; 64(2):211-8. PubMed ID: 19042053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Taylor L; Ashland J; Ye Z; Monberg MJ; Obasaju CK
    Clin Lung Cancer; 2005 Jul; 7(1):40-6. PubMed ID: 16098243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
    J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
    J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
    Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
    Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
    Reck M; Stahel RA; von Pawel J; Karthaus M; Korfee S; Serke M; Schuette WH; Eschbach C; Fink TH; Leschinger MI; Manegold C
    Respir Med; 2010 Jan; 104(1):142-8. PubMed ID: 19818589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
    J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
    Kuribayashi K; Voss S; Nishiuma S; Arakawa K; Nogi Y; Mikami K; Kudoh S
    Lung Cancer; 2012 Mar; 75(3):353-9. PubMed ID: 21890228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
    Li L; Razak AR; Hughes A
    Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience.
    Lainakis G; Zagouri F; Kastritis E; Sergentanis TN; Bozas G; Dimopoulos MA; Papadimitriou CA
    Tumori; 2011; 97(1):25-9. PubMed ID: 21528659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer.
    Sehouli J; Alvarez AM; Manouchehrpour S; Ghatage P; Szczylik C; Zimmermann A; Bauknecht T; Look KY; Oskay-Öezcelik G
    Gynecol Oncol; 2012 Feb; 124(2):205-9. PubMed ID: 22044606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM).
    Pasello G; Marulli G; Polo V; Breda C; Bonanno L; Loreggian L; Rea F; Favaretto A
    Anticancer Res; 2012 Dec; 32(12):5393-9. PubMed ID: 23225442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
    Nakano M; Kusaba H; Makiyama A; Ariyama H; Arita S; Oda H; Esaki T; Takayoshi K; Uchino K; Tamura S; Kumagai H; Iwama E; Shirakawa T; Mitsugi K; Takaishi S; Akashi K; Baba E
    Anticancer Res; 2014 Jan; 34(1):215-20. PubMed ID: 24403465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma.
    Saxena A; Chua TC
    Lung Cancer; 2009 Nov; 66(2):269-70. PubMed ID: 19733416
    [No Abstract]   [Full Text] [Related]  

  • 19. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
    J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.